Status and future directions in the management of pancreatic cancer: potential impact of nanotechnology
- 156 Downloads
Pancreatic ductal adenocarcinoma (PDAC) is typically diagnosed at a late stage, has limited treatments, and patients have poor survival rates. It currently ranks as the seventh leading cause of cancer deaths globally and has increasing rates of diagnosis. Improved PDAC treatment requires the development of innovative, effective, and economical therapeutic drugs. The late stage diagnosis limits options for surgical resection, and traditional PDAC chemotherapeutics correlate with increased organ and hematologic toxicity. In addition, PDAC tumor tissue is dense and highly resistant to many traditional chemotherapeutic applications, making the disease difficult to treat and impeding options for palliative care. New developments in nanotechnology may offer innovative options for targeted PDAC therapeutic drug delivery. Nanotechnology can be implemented using multimodality methods that offer increased opportunities for earlier diagnosis, precision enhanced imaging, targeted long-term tumor surveillance, and controlled drug delivery, as well as improved palliative care and patient comfort. Nanoscale delivery methods have demonstrated the capacity to infiltrate the dense, fibrous tumor tissue associated with PDAC, increasing delivery and effectiveness of chemotherapeutic agents and reducing toxicity through the loading of multiple drug therapies on a single nano delivery vehicle. This review presents an overview of nanoscale drug delivery systems and multimodality carriers at the forefront of new PDAC treatments.
KeywordsChemotherapy Radiation Stem cell Fibrosis Targeted therapy Metastasis
There is no funding to declare.
Compliance with ethical standards
Conflict of interest
S.A.M. holds stock in a small pharmaceutical company, NanoPharmaceuticals LLC, that is developing anticancer drugs. C.S. has no conflicts to declare.
This article does not contain any studies with human participants or animals performed by any of the authors.
- American Cancer Society (2013) Cancer Facts & Figs. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2013.html. Accessed 4 Jan 2018
- Cameron JL, Riall TS, Coleman J, Belcher KA (2006) One thousand consecutive pancreaticoduodenectomies. Ann Surg 244:10–15. https://doi.org/10.1097/01.sla.0000217673.04165.ea CrossRefPubMedPubMedCentralGoogle Scholar
- Campbell PM, Groehler AL, Lee KM, Ouellette MM, Khazak V, Der CJ (2007) K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling. Cancer Res 67:2098–2106. https://doi.org/10.1158/0008-5472.CAN-06-3752 CrossRefPubMedGoogle Scholar
- Le Large TYS, Bijlsma MF, Kazemier G, van Laarhoven HWM, Giovannetti E, Jimenez CR (2017) Key biological processes driving metastatic spread of pancreatic cancer as identified by multi-omics studies. Semin Cancer Biol 44:153–169. https://doi.org/10.1016/j.semcancer.2017.03.008 CrossRefPubMedGoogle Scholar
- Lekstan A, Olakowski M, Jablonska B, Labuzek K, Olakowska E, Filip I, Lampe P (2013) Concentration of gelatinases and their tissue inhibitors in pancreatic inflammatory and neoplastic tumors and their influence on the early postoperative course. Pol Przegl Chir 85:65–72. https://doi.org/10.2478/pjs-2013-0012 CrossRefPubMedGoogle Scholar
- Li Y, VandenBoom TG, Kong D, Wang Z, Ali S, Philip PA, Sarkar FH (2009) Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res 69:6704–6712. https://doi.org/10.1158/0008-5472.CAN-09-1298 CrossRefPubMedPubMedCentralGoogle Scholar
- National Cancer Institute (2018) Pancreatic cancer—patient version. http://www.cancer.gov/research/progress/snapshots/pancreatic. Accessed 4 Jan 2018
- Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM (2014) Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 74:2913–2921. https://doi.org/10.1158/0008-5472.CAN-14-0155 CrossRefPubMedGoogle Scholar
- Rothenberg ML, Abbruzzese JL, Moore M, Portenoy RK, Robertson JM, Wanebo HJ (1996) A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma. Cancer 78:627–632. https://doi.org/10.1002/(SICI)1097-0142(19960801)78:3<627::AID-CNCR43>3.0.CO;2-Y CrossRefPubMedGoogle Scholar
- Sutaria D, Grandhi BK, Thakkar A, Wang J, Prabhu S (2012) Chemoprevention of pancreatic cancer using solid-lipid nanoparticulate delivery of a novel aspirin, curcumin and sulforaphane drug combination regimen. Int J Oncol 41:2260–2268. https://doi.org/10.3892/ijo.2012.1636 CrossRefPubMedPubMedCentralGoogle Scholar
- Kantarjian HM, Wolff RA (eds) (2016) The MD Anderson manual of medical oncology. 3rd edn. McGraw-Hill, New YorkGoogle Scholar
- The Sol Golman Pancreatic Cancer Research Center (2017) What are risk factors for pancreatic cancer? http://pathology.jhu.edu/pancreas/BasicRisk.php?area=baweb. Accessed 5 Jan 2017